Affiliation:
1. Department of Radiotherapy, Baoji Municipal Central Hospital, Baoji, China
2. Department of Anorectal Surgery, BaMunicipal Central Hospital, Baoji, China
3. Department of General Surgery, Ankang Central Hospital, Ankang, China.
Abstract
The purpose of this work was to investigate the effects of curcumin on the biological behavior of colorectal cancer cells through the JAK/STAT3 and RAS/MAPK/NF-κB pathways. Human colorectal cancer HCT116 cells were cultured and divided into a control group and low, medium and high-dose curcumin groups (n =5). HCT116 colorectal cancer cells became long-growing cells after incubation and culture at 37°C. The control group was treated with 15μL phosphate-buffered saline, and the low-dose, medium-dose and high-dose curcumin groups were treated with 20, 40 and 80μmol/L curcumin, respectively. All groups were treated with rel-evant drug intervention, digested and centrifuged for 48h, washed twice with a PBS solution, centrifuged at 1000 rpm for 3 min, and the cells precipitated. The prolif-eration, apoptosis and growth cycle of cells in each group were observed, and the ex-pressions of the JAK/STAT3 and RAS/MAPK/NF-κB pathways and related proteins in each group were studied. Compared with the curcumin low-dose and medium-dose groups, the proliferation ability of the curcumin high-dose group was significantly decreased (P<0.05). When the low-dose and medium-dose curcumin groups were compared with the high-dose curcumin group, the apoptosis ability was significantly increased (P<0.05). When the low-dose and medium-dose curcumin groups were compared, the growth ratio of the G0/G1 phase in the high-dose curcumin group was significantly increased, and the percentage of the S phase was significantly de-creased (P<0.05). Compared with the curcumin low-dose and medium-dose groups, the expression of JAK-STAT3 and RAS/MAPK/NF-κB pathway in the curcumin high-dose group was significantly decreased (P<0.05). The protein expressions of STAT3, RAS, P-P38 and P65 in the curcumin high-dose group were significantly lower than those in the curcumin low-dose and medium-dose groups (P<0.05). Curcumin can inhibit the expression of JAK/STAT3 and RAS/MAPK/NF-κB pathways, block the growth cycle, and inhibit the proliferation and induce apoptosis of colorectal cancer cells, providing a new idea for the clinical treatment of colorectal cancer.
Reference19 articles.
1. Komori A, Taniguchi H, Hamauchi S, Ma-suishi T, Kito Y, Narita Y, Tsushima T, Is-hihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Serum CA19-9 response is an early predictive marker of efficacy of regorafenib in refractory me-tastatic colorectal cancer. Oncology 2017; 93(5): 329-335.
2. Arnold M, Sierra MS, Laversanne M, Soer-jomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66(4): 683-691.
3. Zhang Y, Hou Y, Zhang D. Effects of TYMP gene polymorphism on adjuvant chemothe-rapy after R0 resection in patients with co-lorectal cancer. Cancer Res 2018; 45(7): 5.
4. Chiu HC, Lin YC, Hsieh HM, Chen HP, Wang HL, Wang JY. The impact of com-plications on prolonged length of hospital stay after resection in colorectal cancer: A retrospective study of Taiwanese patients. J Int Med Res 2017; 45(2): 691-705.
5. Li XJ. Basic and clinical research and pro-blems of curcumin in tumor therapy. Chine-se J Pharmacol Toxicol 2019; 33(9): 2.